Navigation Links
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Date:10/1/2007

physicians an important new disease management option that might reduce the need for further therapeutic intervention after a defined treatment period."

Registration Studies for New Drug Application (NDA)

The clevudine Phase 3 registration program includes two 48-week clinical trials designed to demonstrate the superiority of clevudine 30mg over Hepsera (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. Clevudine Study 305 will enroll approximately 376 chronic hepatitis B e-antigen positive patients (HBeAg+), and clevudine Study 306 will enroll approximately 480 chronic hepatitis B e-antigen negative patients (HBeAg-). Pharmasset plans to submit the 48-week data from these studies to the FDA as the basis for clevudine marketing approval.

The primary endpoint for the registration studies is a composite endpoint measuring the proportion of patients with both undetectable serum HBV DNA and normalized liver enzyme (ALT) levels following 48 weeks of monotherapy. The registration studies will also assess improvement in liver histology, hepatitis B e-antigen (eAg) seroconversion, decreases in the reservoir of HBV hepatic cccDNA, and quantitative eAg and surface antigen (sAg). The clevudine registration studies will be conducted in the United States, Canada, Brazil, the United Kingdom, Spain, Greece, Turkey, Romania, Czech Republic, Australia, New Zealand, Singapore, Hong Kong and Taiwan. Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information about the clevudine registration studies.

Assessment of SVR for HBV

After the primary registration data have been obtained at week 48, the Phase 3 studies will continue to week 96 to gather additional safety and efficacy data, as well as to assess clevudine's sustained virologic response (SVR) rate for HBV. SVR is a measure of undet
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an ... for patients to self-inject prescription drugs in the large ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... expected to grow to $220B by 2018, according to ... type of injector that does not exist today for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... AMSTERDAM, October 8 BMEYE B.V., the non-invasive,cardiovascular ... B financing round, raising EUR 6 million. New investors,Earlybird, ... in the,financing, along with other existing BMEYE shareholders as ... BMEYE has successfully been selling Nexfin(TM), an FDA ...
... Oct. 8 Advanced Health Media, LLC (AHM) has ... and related technology for the pharmaceutical and life sciences ... in speaker bureau management, supplying automation and compliance management ... promotional events for more than 200 brands. The ...
Cached Medicine Technology:BMEYE B.V. Completes EUR 6 Million Series B Financing Round 2BMEYE B.V. Completes EUR 6 Million Series B Financing Round 3Advanced Health Media Announces Acquisition of Ephikacy, LLC 2Advanced Health Media Announces Acquisition of Ephikacy, LLC 3
(Date:4/14/2014)... NJ. April 10, 2014. John DeLuca, PhD, and Yael ... Idec to study how persons with multiple sclerosis (MS) ... of Actual Reality to Measure Everyday Life Functional Activity ... research. Dr. DeLuca is senior VP of Research & ... at New York University, is a visiting scientist at ...
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... COLUMBUS, Ohio A new study identifies a molecule ... and suggests that the molecule could be an important ... of tumor progression. , The study of microRNA-135b (miR-135b) ... in the journal Cancer Cell and was ... Cancer Center Arthur G. James Cancer Hospital and ...
(Date:4/14/2014)... --- Depression can hit young fathers hard -- with symptoms ... their children,s lives, a new Northwestern Medicine study has found. ... the first five years of fatherhood for these young men, ... and whom lived in the same home as their children. ... the journal Pediatrics . , This study is the ...
(Date:4/14/2014)... world, many people live and work in dim and ... And as the global population continues to rise and ... spread. , To alleviate the problem, Egyptian researchers ... onto narrow streets and alleyways. The panel is mounted ... angle, where it spreads sunlight onto the street below. ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... Feb. 25 Omnicell, Inc.,(Nasdaq: OMCL ), a ... today that its Board of Directors has approved the,repurchase ... its Common Stock over,the next 12 months. The Company,s ... after a review of the Company,s financial position and,investment ...
... -- Up to 20 percent of patients taking aspirin ... event do not have an antiplatelet response from aspirin, ... at the University at Buffalo have shown. , ... of a second stroke, second heart attack or second ...
... HILL Bacteria mutate for a living, evading antibiotic drugs ... States each year. But as concern about drug-resistant bacteria grows, ... Carolina at Chapel Hill seeks to thwart the bug without ... Mark Schoenfisch and his lab of analytical chemists at UNC ...
... GmbH, a Systems Biology company focussed on high quality ... showcasing its abilities in the analysis of data generated ... Boyle et al published in the January 2008 issue ... of Open Chromatin across the Genome where they identified ...
... 25 Danaher Corporation,(NYSE: DHR ) announced ... Jr. will be presenting at the Citigroup Global ... March 5 at 8:00,a.m. EST. The audio will ... will be archived on, http://www.danaher.com for one ...
... new blockages within 3 years, study finds , , ... a blood clot in their legs (deep vein thrombosis) ... of developing another blood clot within three years, a ... embolism are known collectively as venous thromboembolism. , Researchers ...
Cached Medicine News:Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 3Health News:Many stroke, heart attack patients may not benefit from aspirin 2Health News:Many stroke, heart attack patients may not benefit from aspirin 3Health News:Silica smart bombs deliver knock-out to bacteria 2Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2Health News:Blood Clots in Legs, Lungs Predispose Patients to Repeat Episodes 2
... Technology, multi-frequency, linear micro-surgery transducer. ... very helpful in tight situations. ... a choice transducer for pediatric ... high frequency upper end makes ...
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
Super High Density, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit. Change frequencies on the fly for deeper penetration or for superficial n...
Medicine Products: